Thursday, August 27, 2015 8:00:16 AM
The overall feedback of the 1st International CytoSorb User Meeting in March 2015 in Brussels was so overwhelming positive that we cordially invite you to join the 2nd International CytoSorb User Meeting on Friday, October 2nd 2015, just before start of the 28th ESICM.
Program
11:00 am Registration and Lunch Buffet
12:30 pm Opening (Christian Steiner, CytoSorbents Europe)
Keynote lectures
Chair: Frank Brunkhorst, Jena, Germany
12:40 pm The immune system and its inflammatory response types (Herwig Gerlach, Berlin, Germany)
01:00 pm The impact of Cytosorb on the immune response (John Kellum, Pittsburgh, USA)
Clinical Data 1
Chair: Dana Tomescu, Bucharest, Romania
1.20 pm Early application of CytoSorb in septic shock – A 10vs10 pilot study (Zsolt Molnar, Szeged, Hungary)
1.35 pm CytoSorb in cardiac surgery with cardiopulmonary bypass (CPB) – A 300 patient three-arm-study (Antje-Christin Deppe, Cologne, Germany)
1.50 pm CytoSorb for modulation of SIRS during cardiac surgery with CPB – A 20vs20 pilot study (Jens Kubitz, Hamburg, Germany)
Coffee break
CytoSorb cases and case series 1
2.25 pm CytoSorb in a young patient with toxic shock syndrome (Rotterdam, The Netherlands)
2.35 pm Effect of CytoSorb in a patient with sepsis and liver dysfunction (Dana Tomescu, Bucharest, Romania)
2.45 pm CytoSorb treatment in a child with necrotizing fasciitis (Georgi Arabadzhiev, Stara Zagora, Bulgaria)
2.55 pm CytoSorb use in a case of liver failure (Christian Siebers, Munich, Germany)
3.05 pm Clinical experience in patients with burns (Gerald Ihra, Vienna, Austria)
3.20 pm CytoSorb experiences in H1N1 patients (Abdul Ansari, Leelavathi, India)
3.35 pm Case series of CytoSorb treatments in patients with severe sepsis (Tommaso Laddomada, Zingonia, Italy)
Discussions
Clinical Data 2
Chairs: Marco Maggiorini, Zurich, Switzerland & Detlef Kindgen-Milles, Duesseldorf, Germany
4.00 pm Effect of cytokine adsorption during CPB in cardiac surgery – A 20vs20 pilot study (Martin Bernardi, Vienna, Austria)
4.15 pm Levels of immunosuppressive drugs during CytoSorb treatment (Steffen Mitzner, Rostock, Germany)
4.30 pm The International CytoSorb Registry – Current status (Frank Brunkhorst, Jena, Germany)
Coffee break
CytoSorb cases and case series 2
5.10 pm Case series in post-operative cardiac surgery patients (Karl Träger, Ulm, Germany)
5.25 pm CytoSorb treatments with citrate anticoagulation (Detlef Kindgen-Milles, Duesseldorf, Germany)
5.40 pm Use of CytoSorb in patients with myoglobinemia (Claus Krenn, Vienna, Austria)
5.55 pm A case series of CytoSorb in septic patients (Reshma Basu, Gurgaon, India)
Discussion, Q&A
Moderator: Zsolt Molnar, Szeged, Hungary
Closing remarks
Phil Chan, CEO CytoSorbents Corporation
Dinner and Come together
Download Program
https://www.facebook.com/cytosorbents
Recent CTSO News
- CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- CytoSorbents to Report First Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 04/26/2024 11:00:00 AM
- STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting • GlobeNewswire Inc. • 04/17/2024 11:00:00 AM
- CytoSorbents to Report Fiscal 2023 Operating and Financial Results • GlobeNewswire Inc. • 03/06/2024 12:00:00 PM
- CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 10:20:45 PM
- Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients • GlobeNewswire Inc. • 01/17/2024 12:15:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/08/2024 08:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:49:02 PM
- CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation • GlobeNewswire Inc. • 12/28/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:35:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:33:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:31:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:30:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 02:15:22 PM
- CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering • GlobeNewswire Inc. • 12/13/2023 02:15:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/11/2023 09:10:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 09:10:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:20:25 PM
- CytoSorbents Reports Third Quarter 2023 Financial and Operational Results • GlobeNewswire Inc. • 11/09/2023 09:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:10:54 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM